Literature DB >> 18410853

Mycoplasma pneumoniae encephalopathy: recovery after intravenous immunoglobulin.

Achilleas Attilakos1, Penelope Palaiologou, Evangelia Lagona, Aikaterini Voutsioti, Argirios Dinopoulos.   

Abstract

In a case of Mycoplasma pneumoniae encephalopathy in a 7-year-old girl, the microorganism was identified by serologic and pharyngeal-swab polymerase chain reaction methods. Failure to detect or isolate the pathogen in the cerebrospinal fluid and the significant rapid clinical recovery of the patient after intravenous immunoglobulin administration suggest an immune-mediated mechanism. In critically ill patients with M. pneumoniae encephalopathy, prompt intravenous immunoglobulin treatment may be beneficial and can be considered as a primary or alternative therapeutic approach, especially when use of corticosteroids is insecure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410853     DOI: 10.1016/j.pediatrneurol.2008.01.003

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

1.  Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children.

Authors:  Li-Shen Shan; Xin Liu; Xin-Yuan Kang; Fei Wang; Xiao-Hua Han; Yun-Xiao Shang
Journal:  World J Pediatr       Date:  2017-01-27       Impact factor: 2.764

2.  Early Additional Immune-Modulators for Mycoplasma pneumoniae Pneumonia in Children: An Observation Study.

Authors:  You-Sook Youn; Sung-Churl Lee; Jung-Woo Rhim; Myung-Seok Shin; Jin-Han Kang; Kyung-Yil Lee
Journal:  Infect Chemother       Date:  2014-12-29

3.  Clinical characteristics of refractory mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy.

Authors:  Zhenli Zhu; Tongqiang Zhang; Wei Guo; Yaoyao Ling; Jiao Tian; Yongsheng Xu
Journal:  BMC Infect Dis       Date:  2021-01-28       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.